Bickerstaff George sold $926K of CDNA

Bickerstaff George sold 20,000 shares of CareDx, Inc. (CDNA) at $46.28 ($0.93M total) on 2026-08-05.

Original reporting
SEC EDGAR · Bickerstaff George
Published Aug 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 7:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CDNA
Neutral
low confidence
Mentioned
$CDNA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNANeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 20,000 shares at a stated price, with post-transaction holdings reported.

02

Market read

Traders may monitor insider activity, but this filing alone does not change the company’s outlook.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context, signal quality is low.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-06 for a sale dated 2026-08-05

Background

The article is an SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA).

Company-level read

Ticker impact

$CDNANeutralLow confidence
Context

CareDx director Bickerstaff George filed a Form 4 selling 20,000 shares at $46.2850 on 2026-08-05, totaling about $925.7K.

Expected impact

Likely limited near-term impact; any effect is more sentiment/flow than a fundamental catalyst.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing provides transaction details but no accompanying company-specific news or guidance change.

Market effects

No clear sector read-through from a single director sale.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted by some traders as less routine, potentially increasing short-term skepticism.

Key entities

  • CareDx, Inc.

    Subject of the Form 4 insider transaction disclosure (CDNA).

  • Bickerstaff George

    Director who sold 20,000 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRWVMed

Futures Rise As CoreWeave Calms Debt Jitters, Sparking AI Rebound; Oil Jumps On Hormuz Mines

US futures rise as CoreWeave (CRWV) boosts its revenue forecast, easing debt concerns. AI sector gains momentum with reports of Anthropic's potential $1.5T IPO and OpenAI's $10B quarterly revenue. Nasdaq futures recover Tuesday's losses, while Treasuries near 5% on 10Y. Oil jumps on Strait of Hormuz tensions. CoreWeave shares up 15% premarket. NVDA +5.1%, TSLA +2%, GOOGL +1.2%.

$CDNALow

Why CareDx Stock Soared Today

CareDx (CDNA) shares rose 22% after Q3 revenue surged 39% YoY to $139M, driven by 65% growth in testing services. Testing volumes increased 51% to 75,900, aided by the Naveris acquisition. EBITDA doubled to $30M. The company raised full-year revenue guidance to $525M and adjusted EBITDA targets to $90M-$100M, citing growing interest in precision medicine diagnostics.

$CDNAHighAI 8/10

CareDx Soars 20% on Big Q3 Beat and Guidance Raise

CareDx's shares rose 20% after Q3 revenue increased 39% to $139M, surpassing expectations. The company raised 2026 revenue guidance to $520M-$530M. Adjusted EBITDA doubled to $30M. Natera, a competitor, reports next week, which may indicate market growth or share shifts.